![]() |
市場調査レポート
商品コード
1614778
QUTENZA市場:市場規模、予測、新たな洞察-2032年QUTENZA Market Size, Forecast, and Market Insight - 2032 |
||||||
カスタマイズ可能
適宜更新あり
|
QUTENZA市場:市場規模、予測、新たな洞察-2032年 |
出版日: 2024年12月01日
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
QUTENZA(8%カプサイシン)はTRPV1チャネル作動薬であり、処方強度のカプサイシンを含有する局所システムです。非オピオイド治療薬であり、数カ月に及ぶ疼痛緩和をもたらします。すでに成人では、帯状疱疹後神経痛(PHN)に伴う神経障害性疼痛および糖尿病性末梢神経障害(DPN)に伴う足の神経障害性疼痛の治療薬として承認されています。さらに、同社は特に米国において、術後神経障害性疼痛(PSNP)の治療を含むQUTENZAの適応拡大を計画しています。
今後数年間で、世界中の広範な調査と医療費の増加により、術後痛の市場シナリオは変化します。各社は、病態を治療/改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、QUTENZAの優位性に影響を与える可能性のある機会を模索しています。術後疼痛に対する他の新興製品がQUTENZAに厳しい市場競争をもたらすと予想され、近い将来、後発の新興治療薬が発売されれば、市場に大きな影響を与えるとみられています。
当レポートでは、主要7ヶ国におけるQUTENZA市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。
"QUTENZA Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about QUTENZA for Postoperative pain in the seven major markets. A detailed picture of the QUTENZA for Postoperative pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the QUTENZA for Postoperative pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the QUTENZA market forecast analysis for Postoperative pain in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative pain.
QUTENZA (8% capsaicin) is a TRPV1 channel agonist, a topical system containing prescription-strength capsaicin. It is a non-opioid treatment that provides prolonged pain relief for several months. It is already approved in adults for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and for neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet. Additionally, the company is planning for a label extension of QUTENZA, particularly in the United States, to include the treatment of postsurgical neuropathic pain (PSNP).
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
QUTENZA Analytical Perspective by DelveInsight
This report provides a detailed market assessment of QUTENZA for Postoperative pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
The report provides the clinical trials information of QUTENZA for Postoperative pain covering trial interventions, trial conditions, trial status, start and completion dates.